Study of Episodic Breathlessness in Patients With Lung Cancer or Other Advanced Disease
NCT ID: NCT01138358
Last Updated: 2013-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2010-01-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying experiences of episodic breathlessness in patients with lung cancer or other advanced disease.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To explore the experiences of episodic breathlessness in patients with advanced disease (i.e., primary and secondary lung cancer, chronic obstructive pulmonary disease \[COPD\], chronic heart failure \[CHF\], and motor neuron disease \[MND\]).
* To explore the impact of episodic breathlessness on daily living.
* To explore the individual coping strategies to reduce burden of episodic breathlessness.
OUTLINE: This is a multicenter study.
Patients undergo 1 to 2 interviews to collect data on experiences of breathlessness (in general, at rest, and on exertion including symptom description, interpretation, and meaning); experiences of episodic breathlessness (EB) (at rest and on exertion including symptom description, interpretation, meaning, and definition); trajectory/course of EB (onset/relief, time, and severity) and different types/trajectories of EB; impact of EB (burden, emotional reaction \[panic and fear\], care burden, and dependencies); triggers of EB (causes, situation, and settings) and predictability of EB; management of EB (coping strategies, non-pharmacological and pharmacological management \[including different applications\], worsen/relief, role of care in coping, and emotional/behavior strategies; views on and experiences with services/professionals in management of EB and response to professional advice; and attitudes towards the future, course of the disease, and awareness of prognosis. At the end of the interview, the patient will be asked to draw a figure that illustrates the trajectory of the episode. After the interview, a debriefing will be carried out to give the patient the chance to express worries, potential harm, or any comments about the interview. In addition to the interviews, further information will be collected including demographics, diagnosis and co-morbidities, current pharmacological and non-pharmacological treatments (medical history), functional status (Karnofsky), and breathlessness characteristics (e.g., intensity, frequency, and duration). The interviews will be tape-recorded, transcribed verbatim, and analyzed concurrently using Framework Approach.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
medical chart review
study of socioeconomic and demographic variables
survey administration
quality-of-life assessment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of advanced disease as defined by the following criteria:
* Lung cancer
* Primary lung cancer at all stages (small cell lung cancer \[SCLC\] and non-small cell lung cancer \[NSCLC\])
* Cancer at any site with secondary tumor of the lung (lung metastasis)
* Chronic obstructive pulmonary disease (COPD)
* Stage III or IV of the Global Initiative for Obstructive Lung Disease (GOLD) classification, which includes the airflow limitation measured by spirometry FEV1 \< 50%, FEV1/FVC \< 0.7, and symptoms such as more severe breathlessness, reduced exercise capacity, and repeated exacerbations
* Chronic heart failure (CHF)
* NYHA class II-IV heart disease, which includes symptoms such as dyspnea or palpitation and an increasing limitation of exercise capacity or discomfort at rest
* Motor neuron disease (MND)
* All patients suffering from breathlessness
* Suffering from episodic breathlessness as defined above at any level of severity
PATIENT CHARACTERISTICS:
* Able to give informed consent
* Able to be interviewed
* No cognitive impairment (clinically judged by the principal investigator)
* No limited comprehension of the English language
PRIOR CONCURRENT THERAPY:
* Concurrent disease-oriented therapies (e.g., chemotherapy, radiotherapy, or surgery) allowed
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King's College Hospital NHS Trust
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steffen Simon, MD, MSC
Role: PRINCIPAL_INVESTIGATOR
King's College Hospital NHS Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King's College Hospital
London, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Simon ST, Niemand AM, Benalia H, Voltz R, Higginson IJ, Bausewein C. Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med. 2012 Dec;15(12):1374-81. doi: 10.1089/jpm.2012.0249. Epub 2012 Oct 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UKM-KCH-EB-V4
Identifier Type: -
Identifier Source: secondary_id
EU-21039
Identifier Type: -
Identifier Source: secondary_id
CDR0000674580
Identifier Type: -
Identifier Source: org_study_id